483 Final analysis of virological outcomes and resistance during 5 years of adefovir dipivoxil monotherapy in HBeAg-negative patients
Katyna Borroto–Esoda(Gilead Sciences (United States)), Jean–Michel Pawlotsky(Université Paris-Est Créteil), A. Snow, S. Locamini, E. Zoulim, Steven L. Chuck(Gilead Sciences (United States)), Sarah Arterburn(Gilead Sciences (United States)), S. Hadziyannis
Cited by 19
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
|New England Journal of Medicine|2006|886
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
|Gastroenterology|2006|882
Infections with<i>Cryptococcus neoformans</i>in the Acquired Immunodeficiency Syndrome
|New England Journal of Medicine|1989|801